AU2001243515A1 - Combination drug therapy - Google Patents

Combination drug therapy

Info

Publication number
AU2001243515A1
AU2001243515A1 AU2001243515A AU4351501A AU2001243515A1 AU 2001243515 A1 AU2001243515 A1 AU 2001243515A1 AU 2001243515 A AU2001243515 A AU 2001243515A AU 4351501 A AU4351501 A AU 4351501A AU 2001243515 A1 AU2001243515 A1 AU 2001243515A1
Authority
AU
Australia
Prior art keywords
drug therapy
combination drug
combination
therapy
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001243515A
Inventor
Paul Calabresi
James W. Darnowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Original Assignee
LIFESPAN PARTNER RHODE ISLAND
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LIFESPAN PARTNER RHODE ISLAND, Rhode Island Hospital filed Critical LIFESPAN PARTNER RHODE ISLAND
Publication of AU2001243515A1 publication Critical patent/AU2001243515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
AU2001243515A 2000-03-08 2001-03-08 Combination drug therapy Abandoned AU2001243515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18785200P 2000-03-08 2000-03-08
US60187852 2000-03-08
PCT/US2001/007472 WO2001066144A2 (en) 2000-03-08 2001-03-08 Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity

Publications (1)

Publication Number Publication Date
AU2001243515A1 true AU2001243515A1 (en) 2001-09-17

Family

ID=22690748

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001243515A Abandoned AU2001243515A1 (en) 2000-03-08 2001-03-08 Combination drug therapy

Country Status (3)

Country Link
US (1) US6849599B2 (en)
AU (1) AU2001243515A1 (en)
WO (1) WO2001066144A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
DE602004024536D1 (en) * 2003-07-07 2010-01-21 Van Andel Res Inst INHIBITION OF TUMOR ANGIOGENESIS BY A COMBINATION OF THROMBOSPONDIN-1 AND INHIBITORS OF THE VASCULAR ENDOTHEL GROWTH FACTOR
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
AU2005219413A1 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
EP2364970A1 (en) * 2005-08-19 2011-09-14 Vertex Pharmaceuticals Incorporated Processes and intermediates
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
US8118969B2 (en) * 2006-11-30 2012-02-21 Illinois Tool Works Inc. Water-based polychloroprene adhesive
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
AR082806A1 (en) * 2010-08-30 2013-01-09 Sun Pharma Advanced Res Co Ltd STABLE PHARMACEUTICAL COMPOSITION
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5840692A (en) 1990-02-22 1998-11-24 Allegheny University Of The Health Sciences Peptide fragments and analogs of thrombospondin
KR930702985A (en) 1991-02-21 1993-11-29 스튜어트 알.슈터 Treatment of Esophageal Cancer
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
EP1393729A3 (en) 1991-11-15 2004-03-17 Smithkline Beecham Corporation Combination chemotherapy involving topotecan and a platinum coordination compound
AP9300587A0 (en) 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5670507A (en) 1995-01-27 1997-09-23 Cell Therapeutics, Inc. Method for reversing multiple drug resistant phenotype
ES2388248T3 (en) 1997-03-31 2012-10-11 Boston Scientific Scimed Limited Dosage form comprising taxol in crystalline form
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
AU8921398A (en) 1997-08-27 1999-03-16 Merck & Co., Inc. A method of treating cancer
EP1019530A1 (en) 1997-08-27 2000-07-19 Merck & Co., Inc. A method of treating cancer
WO1999010523A1 (en) 1997-08-27 1999-03-04 Merck & Co., Inc. A method of treating cancer
AU762986B2 (en) 1998-04-22 2003-07-10 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids

Also Published As

Publication number Publication date
US20020107191A1 (en) 2002-08-08
WO2001066144A2 (en) 2001-09-13
WO2001066144A3 (en) 2002-03-28
US6849599B2 (en) 2005-02-01

Similar Documents

Publication Publication Date Title
AU2001252135A1 (en) Therapeutic agents
AU5259100A (en) Medicament
AU2002222853A1 (en) Therapeutic compounds
AU2001269529A1 (en) Medicine comprising dicyanopyridine derivative
AUPQ899700A0 (en) Probiotic recolonisation therapy
AU2002231039A1 (en) Therapeutic stockings
AU2002253039A1 (en) Tramadol-based medicament
AU2002210463A1 (en) Transdermal therapeutic system
AU2001274548A1 (en) Syringe
AU7377200A (en) Combination therapy including camptothecin
AU6900201A (en) Breath-controlled therapeutic inhalation device
AU2001243515A1 (en) Combination drug therapy
AU2002221099A1 (en) Combination drugs
AU2451500A (en) Therapeutic agents
AU2001232244A1 (en) Drug comprising combination
AU2002335667A1 (en) Modified reoviral therapy
AU2002218750A1 (en) Photoactivated drug therapy
AU2001273903A1 (en) Therapeutic agents
AU2001286341A1 (en) Therapeutic bio-energy unit
AU2001247841A1 (en) Medical procedure
AU2001268653A1 (en) Combination hiv therapy including camptothecin
AU2001272718A1 (en) Medicaments
AU5973600A (en) Therapeutic agents
AU3714800A (en) Hiv therapy
AU2001275696A1 (en) Therapeutic agent